## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 Congress Avenue, Suite 2400 AUSTIN, TEXAS 78701-2978 WWW.FULBRIGHT.COM

MARK B. WILSON PARTNER MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035 TELEPHONE: (512) 474-5201

(512) 536-4598 FACSIMILE:

February 17, 2009

Commissioner for Patents

Attention: Certificates of Correction Branch

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being electronically filed with the United States Patent Trademark Office via EFS-Web on the date below

February 17, 206 Mark B. Wilson Date

RE:

Request for Certificate of Correction

Patent No. 6,623,930 Dated: September 23, 2003 Application No. 09/940,173 Confirmation No.: 5375

Entitled: "INHIBITION OF HUMAN TELOMERASE BY A G-OUADRUPLEX-

INTERACTION COMPOUND" - Sean M. Kerwin et al.

Our Ref.: UTSB:679USD2

Commissioner:

Attached is form PTO-1050. Errors of a minor nature are thereon corrected. The errors are due to applicant. A Certificate of Correction is requested under 35 U.S.C. § 255.

The required fee set forth in 37 C.F.R. § 1.20(a) is included. If the fee is inadvertently omitted, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, or should an overpayment be included, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/UTSB:679USD2.

Mark B. Wilson

MBW/ist Attachment

## UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO. : 6,623,930

DATED : September 23, 2003
INVENTOR(S) : Sean M. Kerwin et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 1, lines 13-17, delete

"The government may own rights in the present invention pursuant to contract number U19CA-67760-02, and contract number NCDDG, CA67760 from the National Cancer Institute, and contract number CA4975 1 and contract number CA77000 from the National Institutes of Health." and insert

--This invention was made with government support under contract No. U19CA67760-02 and National Cooperative Drug Discovery Grant No. CA67760 from the National Cancer Institute, and contract numbers CA49751 and CA77000 from the National Institutes of Health. The government has certain rights in the invention.—therefor.

MAILING ADDRESS OF SENDER: Mark B. Wilson FULBRIGHT & JAWORSKI L.L.P. 600 Congress Ave., Suite 2400 Austin, Texas 78701 PATENT NO.6,623,930 No. of add'l. copies @ 50¢ per page